JOHNSON & JOHNSON |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.8 EUR | -1.48% |
|
0.00% | -3.46% |
| 12:00pm | The battle over J&J's bankruptcy plan to end talc lawsuits | RE |
| 07-03 | Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 823B | ||||||
| 320B | ||||||
| 295B | ||||||
| 239B | ||||||
| 220B |
